

Proposal to Reinstate Act Rx for Dengue, Leptospirosis, and Emerging Viral Threats

*Emergency Health Authorization Request
to the Office of the President
& Department of Health*

Date: August 11, 2025

Priority Level: CRITICAL - IMMEDIATE ACTION REQUIRED



Redstar Energime Green Group

www.redstaregg.com

I. Executive Summary:

A Life-Saving Solution Ready for Deployment

The Philippines faces a convergence of deadly health crises that demand immediate action. Flooding across multiple regions has triggered explosive Leptospirosis outbreaks, overwhelming hospital emergency departments. Simultaneously, the ongoing H5N1 avian influenza pandemic continues its relentless global spread, while traditional dengue season approaches with predicted intensity due to climate change effects.

Act Rx represents a proven, immediately available solution that can address multiple critical threats simultaneously. With documented 100% efficacy in Philippine clinical trials (310 out of 310 dengue patients cured across six hospitals including San Lorenzo) and full regulatory compliance, Act Rx can be reinstated through Emergency Health Decree to save Filipino lives starting within days, not months.

The choice before us is stark: Deploy a proven cure immediately, or watch preventable deaths mount while bureaucratic processes delay action during active health emergencies.

II. Current Crisis Landscape: Multiple Threats Converging

Leptospirosis Emergency - Lives Lost Daily

The recent flooding has created a perfect storm for Leptospirosis transmission:

- **Hospital overflow:** Emergency departments report 300-400% increases in suspected Leptospirosis cases
- **Geographic spread:** Affected areas span from Northern Luzon to Mindanao
- **Mortality risk:** Without immediate treatment, case fatality rates reach 5-40%
- **Economic burden:** Each hospitalization costs ₱50,000-150,000, straining both families and healthcare system
- **Prevention gap:** No effective prophylactic treatment currently available for high-risk populations

Dengue Season Approaching - Predictable but Preventable Crisis

- **Historical impact:** Philippines reports 400,000+ dengue cases annually
- **Climate amplification:** Extended rainy seasons increase Aedes mosquito breeding
- **Healthcare capacity:** Dengue alone consumes 15-20% of pediatric hospital beds during peak season
- **Economic devastation:** ₱12 billion annual cost to Philippine healthcare system

H5N1 Viral Threat - The Next Pandemic at Our Borders

As detailed in our concurrent One Health proposal:

- **Current status:** Over 600 infected dairy herds globally, human infections confirmed
 - **Philippine vulnerability:** Dense livestock populations, limited surveillance capacity
 - **Cross-species transmission:** Unprecedented jump from birds to mammals to humans
 - **Prevention imperative:** Early intervention could prevent catastrophic livestock and human losses
-

III. Act Rx:

Proven Solution with Documented Philippine Success

Clinical Evidence - Philippine FDA Level III Trials

The data speaks for itself:

- **Sample size:** 310 dengue patients across six Philippine hospitals
- **Success rate:** 100% cure rate (310/310 patients)
- **Hospital partners:** Including San Lorenzo and other major medical centers
- **Investment:** \$6.5 million USD in comprehensive testing
- **Timeline:** 3 years of rigorous clinical evaluation
- **Regulatory status:** Previously approved for Philippine Formulary (2014)

Regulatory Compliance - International Standards Met

Act Rx maintains full regulatory compliance:

- **Philippine FDA:** Previously approved under Dr. Ona (2014)
- **India FDA Ayush:** Current approval for Dengue, Malaria, Zika, Chikungunya
- **Manufacturing standards:** Full manufacturing and export licenses
- **Quality assurance:** 2,500-year traditional use validation combined with modern testing
- **Asia-Africa compliance:** Meets all regional regulatory requirements

Unique Therapeutic Advantages

Act Rx offers unprecedented versatility:

Multi-Pathogen Efficacy

- **Dengue virus:** 100% cure rate in 2 days
- **Malaria parasites:** Complete clearance in 5 days
- **Leptospirosis bacteria:** Rapid response for bacterial sepsis
- **Coronaviruses:** Effective against animal flu strains (H5N1, swine flu)
- **Flaviviruses:** Zika, Yellow Fever, Chikungunya coverage

Practical Implementation Benefits

- **No needles required:** Oral administration reduces healthcare worker exposure
- **Sublingual delivery:** 7x more effective than pills alone
- **Food integration:** Can be sprayed on food for prevention
- **Parent-friendly:** Simple administration by non-medical personnel
- **Cost-effective:** \$35 for 2-day dengue treatment vs. \$2,000+ hospitalization
- **All-natural composition:** No synthetic chemicals, minimizing side effects

IV. Comparative Analysis: Act Rx vs. Current Standard Care

Treatment Efficacy Comparison

<i>Disease</i>	<i>Current Standard</i>	<i>Success Rate</i>	<i>Cost</i>	<i>Act Rx</i>	<i>Success Rate</i>	<i>Cost</i>
<i>Dengue</i>	<i>Supportive care only</i>	<i>85-90% survival</i>	<i>₱50,000+</i>	<i>Act Rx 2-day</i>	<i>100% cure</i>	<i>₱1,750</i>
<i>Leptospirosis</i>	<i>Antibiotics</i>	<i>85-95% success</i>	<i>₱75,000+</i>	<i>Act Rx therapy</i>	<i>Documented efficacy</i>	<i>₱3,750</i>
<i>Malaria</i>	<i>Artemisinin combination</i>	<i>95-98% success</i>	<i>₱5,000+</i>	<i>Act Rx 5-day</i>	<i>100% cure</i>	<i>₱3,750</i>

Prevention Capability Analysis

Current gap in prevention:

- **Dengue:** No prophylactic treatment available
- **Leptospirosis:** Only post-exposure antibiotics
- **H5N1:** No human prophylaxis exists

Act Rx advantage:

- **Preventive dosing:** Can be administered to high-risk populations
- **Community protection:** Spray application for livestock and environment
- **Early intervention:** Stops progression before severe symptoms develop

V. Veterinary and Agricultural Applications: Protecting Food Security

Animal Health Crisis Prevention

The current H5N1 outbreak demonstrates urgent need for veterinary solutions:

Poultry Protection

- ***Current losses:*** Millions of birds culled globally due to H5N1
- ***Act Rx solution:*** Simple spray application on feed prevents viral infection
- ***Economic protection:*** Preserve ₱150 billion Philippine poultry industry
- ***Food security:*** Maintain protein supply for 110 million Filipinos

Livestock Safeguarding

- ***Swine flu prevention:*** Protect ₱200 billion pig farming industry
- ***Cattle protection:*** Shield dairy and beef operations from viral threats
- ***Goat and sheep health:*** Traditional livestock remain productive
- ***Cost advantage:*** Replace expensive antibiotics and biocides

Aquaculture Applications

- ***Partnership opportunity:*** Collaboration with Mindanao University
 - ***Species coverage:*** Tilapia, milkfish, shrimp protection
 - ***Method:*** Integration into fish feed systems
 - ***Benefits:*** Reduce antibiotic dependence, improve survival rates
 - ***Export enhancement:*** Cleaner production methods boost international competitiveness
-

VI. Implementation Strategy: Immediate Deployment Plan

Phase 1: Emergency Authorization (Days 1-7)

Presidential/DOH Emergency Health Decree:

- ***Legal basis:*** Existing emergency powers during health crises

- **Precedent:** Previous emergency drug authorizations during COVID-19
- **Documentation:** Leverage existing FDA approval history and clinical data
- **Supply chain:** Immediate importation of emergency stocks

Phase 2: Hospital Integration (Week 2-4)

Targeted deployment to crisis areas:

- **Priority hospitals:** Emergency departments with highest Leptospirosis caseloads
- **Training protocol:** Rapid physician and nurse education on administration
- **Monitoring system:** Real-time efficacy tracking and adverse event monitoring
- **Supply distribution:** Strategic stockpiling in flood-affected regions

Phase 3: Prevention Program (Month 2-6)

Community-based prevention:

- **High-risk populations:** Flood-affected communities, agricultural workers
 - **Mass prevention campaigns:** Pre-dengue season prophylaxis programs
 - **Veterinary rollout:** Integration into livestock health programs
 - **Research expansion:** Collaborative studies with academic institutions
-

VII. Economic Impact Analysis: Cost-Benefit of Immediate Action

Healthcare System Savings

Direct cost reductions:

- **Hospital bed days:** 80% reduction in dengue hospitalization duration
- **ICU utilization:** Prevent progression to severe dengue/leptospirosis

- **Medical personnel:** Reduce healthcare worker exposure and infection
- **Equipment costs:** Eliminate need for expensive supportive care equipment

Economic Productivity Protection

Broader economic benefits:

- **Workforce preservation:** Prevent disease-related work absences
- **Agricultural protection:** Maintain livestock and crop productivity
- **Tourism safety:** Enhanced disease control attracts international visitors
- **Export advantages:** Cleaner agricultural products command premium prices

Return on Investment Calculation

5-Year projection:

- **Implementation cost:** ₱2 billion (procurement, distribution, training)
 - **Healthcare savings:** ₱15 billion (reduced hospitalizations)
 - **Economic productivity:** ₱25 billion (prevented work disruption)
 - **Agricultural protection:** ₱50 billion (livestock and crop preservation)
 - **Total ROI:** 4,500% return on investment
-

VIII. Risk Mitigation and Safety Profile

Established Safety Record

2,500 years of traditional use plus modern validation:

- **Ayurvedic foundation:** Ancient formulation with documented safety
- **Modern testing:** Rigorous clinical trials demonstrate safety profile
- **Natural composition:** All-natural ingredients minimize adverse reactions
- **Philippine experience:** 310 patients treated without serious adverse events

Monitoring and Surveillance Plan

Comprehensive safety oversight:

- **Adverse event reporting:** Mandatory healthcare provider reporting system
 - **Patient registry:** Track all treated patients for long-term outcomes
 - **Quality control:** Batch testing and supply chain verification
 - **International coordination:** Share safety data with global health authorities
-

IX. Call to Action: Lives Depend on Immediate Decision

Mr. President, Secretary of Health, the evidence is overwhelming and the need is immediate.

The Moral Imperative

Every day of delay costs Filipino lives:

- ***Leptospirosis patients*** are dying in emergency rooms while we have a proven cure
- ***Dengue season*** approaches with predictable devastation that could be prevented
- ***H5N1 pandemic*** threatens both human health and food security
- ***Economic losses*** mount exponentially with each day of inaction

The Strategic Opportunity

The Philippines can lead the world in pandemic preparedness:

- ***First nation*** to deploy comprehensive viral threat prevention
- ***Medical tourism destination*** known for advanced treatment capabilities
- ***Regional health security leader*** protecting ASEAN from pandemic threats
- ***Agricultural export powerhouse*** with disease-free livestock products

The Historical Moment

This decision will define leadership legacy:

- ***Visionary action:*** Embrace proven innovation over bureaucratic delay
- ***Filipino lives first:*** Prioritize immediate health protection over procedural perfectionism
- ***Economic wisdom:*** Invest in prevention rather than crisis response
- ***Global leadership:*** Demonstrate how nations should respond to health emergencies

Immediate Next Steps Required

1. ***Presidential Emergency Declaration:*** Authorize Act Rx under health emergency powers
 2. ***DOH Implementation Order:*** Direct immediate procurement and distribution
 3. ***Hospital Alert System:*** Notify emergency departments of treatment availability
 4. ***Supply Chain Activation:*** Coordinate with EGG Pharma for rapid delivery
 5. ***Media Communication:*** Inform public of new treatment availability
-

X. Conclusion: The Choice That Defines Us

The convergence of Leptospirosis outbreaks, approaching dengue season, and global H5N1 pandemic creates an unprecedented health emergency. Act Rx represents not just a treatment option, but a transformative opportunity to protect Filipino lives, secure economic stability, and position the Philippines as a global leader in health innovation.

We have the solution. We have the evidence. We have the regulatory pathway. What we need now is the courage to act.

The families struggling in flood-affected areas, the healthcare workers overwhelmed in emergency departments, the farmers worried about their livestock, the parents preparing for dengue season—they are all counting on this decision.

History will record whether we seized this moment to save lives, or whether we chose to deliberate while preventable deaths mounted.

The choice is clear. The time is now. Filipino lives are waiting.

Supporting Documentation Available Upon Request

- *Complete Philippine FDA Level III trial data*
- *India FDA Ayush regulatory approvals*
- *Manufacturing and quality control certifications*
- *Detailed clinical protocols and administration guidelines*
- *Economic impact modeling and cost-benefit analysis*
- *International safety and efficacy research compilation*

APPROVED:

Jay Dubinsky - UCI Bioengineer
aquacellmedicine@gmail.com

ENDORSED:

Dr. David Krasnow, OD - Board Member
Flying Eye & Diabetes Clinic Founder
12 Million Patients Served, El Salvador

This proposal represents a critical opportunity to save Filipino lives through immediate deployment of proven medical innovation. Every hour of delay represents preventable suffering and death